Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Japanese Pharma Industry Group Visits UCB
September 22, 2008
- RAD001 Granted Priority Review Status in the US
September 22, 2008
- Meiji Seika, Meiji Dairy to Integrate Businesses
September 22, 2008
- Will Distribution Practices Be Improved? Part 2
September 22, 2008
- NovoRapid 30 Mix Has Turned Out to Be Global Blockbuster: Novo Nordisk Pharma
September 22, 2008
- Kissei Licenses Monoclonal Antibody from Y's Therapeutics
September 22, 2008
- Global Market for Monoclonal Antibodies to Expand to $49 Bil. in 2013: Datamonitor
September 22, 2008
- Eli Lilly Japan Aims at $1 Bil. in 2010, $2Bil. in 2015: Mr Zulueta
September 22, 2008
- Delegates Criticize JPA Leaders over Qualification for Store Managers
September 22, 2008
- World's 1st Drug for Idiopathic Pulmonary Fibrosis Recommended for Approval
September 15, 2008
- Shionogi to Enter US Market by Acquiring Sciele
September 15, 2008
- DSP to Design Independent US Marketing System by Mid-2009
September 15, 2008
- Kowa to Start Independent Marketing of Livalo in the US in 2010
September 15, 2008
- PMDA Considers New System to Ensure Greater Post-Marketing Safety
September 15, 2008
- Otsuka to Codevelop Drug for Dry AMD with Acucela
September 15, 2008
- NICE to Recommend Lucentis to Treat Wet AMD under Health Insurance
September 15, 2008
- VEGF Trap-Eye Improves Vision in Patients with AMD: Bayer, Regeneron
September 15, 2008
- Pramipexole Improves Symptoms Associated with RLS: BI
September 15, 2008
- Greater Incentives Necessary to Further Increase Use of Generics: Dr Muto
September 15, 2008
- Novartis Has 8 NDAs Pending: Most Ever
September 15, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…